Improving access to pre-exposure prophylaxis for HIV prescribing in a primary care setting

Although emtricitabine–tenofovir was approved for HIV pre-exposure prophylaxis (PrEP) in 2012, use by persons at risk of acquiring HIV has been limited. Because many primary care providers lacked familiarity and comfort prescribing PrEP, at our institution PrEP prescribing was concentrated among the...

Descripción completa

Detalles Bibliográficos
Autores principales: Lumsden, Joshua, Dave, Amish J, Johnson, Camille, Blackmore, Craig
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Quality Improvement Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9109090/
https://www.ncbi.nlm.nih.gov/pubmed/35551096
http://dx.doi.org/10.1136/bmjoq-2021-001749

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9109090/
https://www.ncbi.nlm.nih.gov/pubmed/35551096
http://dx.doi.org/10.1136/bmjoq-2021-001749

Ejemplares similares